Citation for published version (APA):
APOE ε4 is also required in TREM2 R47H variant carriers for Alzheimer’s disease to develop.

Christina E. Murray¹, Andrew King²,³, Claire Troakes³,⁴, Angela Hodges⁵, Tammaryn Lashley¹.

²Queen Square Brain Bank for Neurological disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 1PJ, UK.
²Department of Clinical Neuropathology, Kings College Hospital, London, UK
³London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK
⁴Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
⁵Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK.

Corresponding author:

Dr Tammaryn Lashley,
Queen Square Brain Bank,
Department of Molecular Neuroscience,
Institute of Neurology,
London,
WC1N 3BG, UK

Email: T.Lashley@ucl.ac.uk
Tel: 0207 679 4194

Word Count: 1492
Number of references: 15
In late-onset Alzheimer’s disease (AD), the ε4 allele of the apolipoprotein E gene (APOE) is the major known genetic risk factor [1]. In 2013 two research groups reported the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2), is associated with AD by almost as much as APOE ε4 [2,3]. A loss-of-function R47H mutation in TREM2 is also one of the strongest single allele genetic risk factors for AD [2,3], providing a link between microglia dysfunction and AD pathogenesis. TREM2 encodes a single-pass type I membrane protein that forms a receptor-signaling complex with the TYRO protein tyrosine kinase-binding protein (TYROBP) triggering immune responses in certain macrophages and dendritic cells.

At Queen Square Brain Bank for Neurological disorders (Institute of Neurology, UCL) and London Neurodegenerative Diseases Brain Bank (Institute of Psychiatry, Psychology and Neuroscience, KCL) we have identified 16 TREM2 variant cases, 11 cases with neuropathological confirmation of AD and 5 cases identified as normal controls with no underlying AD pathology at the time of death (Figure 1). The cohort includes 5 AD cases with R47H variant (cases 6-10) that also carry an APOE ε4 allele; an AD case carrying an R47H variant with no APOE ε4 allele (case 5) and the remaining 5 AD cases carrying different TREM2 variants described previously to be associated with AD pathogenesis (cases 1-4) or an additional PS1 mutation (case 11). Two normal controls carry the R47H variant and do not carry an APOE ε4 allele (cases 15 and 16), two controls have a different TREM2 mutation and the remaining R47H control case died at young age (cases 12-14). This is a small cohort of pathologically confirmed cases that potentially link the R47H TREM2 variant and APOE ε4 allele with a diagnosis of AD. In our cohort three other TREM2 variants (T96K, Q22X, D87N) are present with an APOE ε4 allele, suggesting that APOE ε4 allele may also be the driving factor rather than then TREM2 variant. Where the presence of the R47H TREM2 variant is found in the absence of APOE ε4 AD does not manifest (Figure 1). The single AD case in this cohort (case 5) with a R47H variant which lacked an APOE ε4 allele, pathologically had an additional diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP subtype A). This case had a much later age of onset compared to the other cases and the additional diagnosis was more than typically observed when a secondary TDP-43 pathology is seen in elderly patients with AD. These findings are supported by pathologically confirmed cases reported in the literature. Korvatska et al reported a large late onset family in which the R47H variant co-segregated with 75% of cases [4]. The R47H variant was confirmed in 11 individuals affected by AD, and all 11 cases also carried an APOE ε4 allele. Three unaffected individuals were also shown to carry the R47H variant: two died before the typical age of late onset AD and one died at age 87, was both cognitively normal and an APOE ε3ε3 carrier [4]. Yuan et al included ten R47H variant pathologically confirmed AD cases all of which carried an APOE ε4 allele [5]. Krasemann et al reported the R47H variant cases used in their study
also carried an APOE ε4 allele [6]. Studies that have been unable to show a significant correlation between carrying both the R47H variant and an APOE ε4 allele [3,7]. Including GWAS studies from clinical samples without pathological confirmation and or including other TREM2 variants in the analysis and not just the R47H variant or correlated APOE ε4 status in AD cases without a R47H variant [3,7].

Many TREM2 variants have been identified which can impact TREM2 localization within the cell. The R47H variant is found on the extracellular portion of the protein and impacts ligand binding [8]; the expression and protein levels remain unaltered [7]. Unlike other variants, TREM2 containing the R47H variant is mostly localized to the trans-Golgi network rather than the endoplasmic reticulum (ER), comparable to the wild-type receptor [9,10]. Studies employing a TREM2 R47H-Fc chimeric protein revealed the R47H variant significantly reduces TREM2 binding to cells [8] and the three isoforms of APOE [11]. Although binding seems to occur independently of APOE isoforms [11,12], several studies demonstrate that TREM2-APOE binding is not dependent on lipid loading [11]. However, others have found that lipidation was necessary to drive TREM2 binding [12] and lipid association was reported to be necessary for TREM2 binding to APOE from cynomolgus macaque CSF and serum [11]. APOE binding to TREM2 was found to induce TREM2 signaling in reporter cell lines; though how its binding to TREM2 would alter signaling in vivo remains to be determined. As APOE can bind to apoptotic cells and amyloid plaques [11], it has been proposed that an interaction between TREM2 and APOE may indirectly allow it to mediate recognition and phagocytosis of these substrates. A study by Krasemann et al. shows the mechanism controlling the transition from homeostatic to neurodegenerative microglia (M GnD) is dependent on APOE. They also show that the removal of TREM2 locks microglia into a homeostatic state blocking the formation of M GnD microglia, similarly to the effects of APOE deficiency. Pathway analysis identified APOE as a major upstream inducer of the M GnD microglia phenotype, and the authors turned to TREM2 because it has high affinity for anionic phospholipids in complex with APOE on the surface of apoptotic neurons or in lipoproteins. Krasemann et al also found that acquisition of M GnD microglia is dependent on APOE and mediated through TREM2 signaling [6].

We propose that pathologically confirmed AD cases carrying the R47H variant also carry an APOE ε4 allele and without an APOE ε4 allele AD does not develop. As both genetic variants have been confirmed to increase the risk of AD the likelihood of receiving donated brains with both variants is also increased. Our observations from cases donated and published studies suggest that APOE ε4 allele moderates AD risk in TREM2 R47H variants; therefore you are unlikely to develop AD without having an APOE ε4 allele if you are TREM2 R47H positive. No pathological studies have confirmed the lack of underlying AD pathology in R47H variant cases without an APOE ε4 allele and
there is a greater need to obtain pathological confirmation in these cases to validate a connection between the two genetic risk factors. The identification of the TREM2 locus as a risk factor for AD is important to understand the mechanism by which it influences disease risk. Evidence based on pathologically confirmed cases highlights the association of the R47H variant and APOE ε4 allele in AD although further investigations are needed to determine the effect of APOE on TREM2. The link between innate immunity and AD pathogenesis, highlighted by genetics studies, emphasizes the importance of exploring APOE function in microglia.

Acknowledgments
We acknowledge funding from Alzheimer’s Research UK Senior fellowship (TL), Alzheimer’s Research UK PhD studentship (CM). The Queen Square Brain Bank is supported by the Reta Lila Weston Institute for Neurological Studies and the Progressive Supranuclear Palsy (Europe) Association. The London Neurodegenerative Diseases Brain Bank is funded by the MRC and by the Brains for Dementia Research project (jointly funded by Alzheimer’s Research UK and Alzheimer’s Society).

Conflict of interests
The authors declare no conflict of interest in relation to this work.

Author contributions
CT, AH, AK provided the cases from the London Neurodegenerative Disease Brain Bank and detailed pathological and genetic data. TL and CM conceived the study performed the data collection and immunohistochemical staining, prepared the figures and wrote the manuscript. All authors read and approved the final manuscript

Figure 1: Case demographics and comparison of pathological hallmarks in a TREM+ APOE ε4- control case (case 16; panels a and b) and TREM+ APOE ε4+ Alzheimer’s disease case (case 9; panels c-f). The table details the case demographics of the TREM2 variant cases identified at Queen Square Brain Bank and Institute of Psychiatry, Psychology and Neuroscience. Immunohistochemical analysis of R47H variant carriers shows no Aβ deposition in TREM2 R47H+ APOE ε4- (a and b) compared to the characteristic Alzheimer’s disease pathology observed in the TREM2 R47H+ APOE ε4+ cases: Aβ plaques observed in the hippocampus (c) and frontal cortex (d), along with tau immunohistochemistry in the hippocampus (e) and occipital cortex (f) Scale bar in a represents 500µm in a, c and f; 30µm in b and d; 100 µm in e.
References


9. Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, Yoon SY. Disease-Associated Mutations of

